Brigham and Women's Hospital, Division of Sleep Medicine
Boston, Massachusetts, 02115, United States
NCT Number: NCT00555750
The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S. Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in the United States as LUNESTA.
Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that can be reversed by two months of eszopiclone for the primary insomnia
Looking for future studies?
Notify Me25 year–55 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02115, United States
Insomnia is the most common sleep disorder, affecting nearly one-third of all adults in any given year, and chronically affecting 10-15% of the adult population. Reduced sleep time, independent of insomnia, has been associated with a variety of deleterious long term effects, including an increased risk of incident myocardial infarction and symptomatic diabetes. Chronic partial sleep loss or insomnia may impair glucose metabolism in the short term and are associated with the development of diabetes in the long term. Although the extent of sleep loss is more acute in the laboratory-based 'sleep debt' studies of healthy volunteers, chronic primary insomnia patients exhibit 'hyperarousal' (hypercortisolemia in the afternoon and evening, accelerated metabolism) similar to that seen with acute sleep deprivation. In addition, degradations of sleep quantity and quality in primary insomnia have been attributed to cognitive and somatic hyperarousal in the sleep setting. study examines and quantifies in adult men and women the link between primary insomnia and impaired glucose tolerance. This study examines the extent which adequate treatment of primary insomnia reverses impairments of glucose metabolism. If abnormalities of glucose metabolism are reversible, this study will demonstrate the importance of treatment of chronic primary insomnia.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3mg tablet, by mouth nightly 30 min before bed, for two months
Other names: Lunesta
inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
Time frame: baseline and 2 months post-treatment
Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.
Time frame: baseline and 2 months post-treatment
Change over two months in 1st phase Insulin secretion
Time frame: baseline and 2 months post-treatment
Insulin sensitivity index (SI) "was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma." [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)
Time frame: baseline and 2 months post-treatment
Glucose effectiveness was defined as "the ability of glucose itself to enhance its own disappearance independent of an increment in insulin." [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)
Time frame: baseline and 2 months post-treatment
Difference in HbA1c levels following two months treatment with eszopiclone versus placebo
Time frame: baseline
Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast
Time frame: two months post-treatment
Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
Time frame: baseline
Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
Time frame: 2 months post-treatment
Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast
Time frame: baseline and 2 months post-treatment
At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 ("very alert") to 9 ("very sleepy, fighting sleep, an effort to keep awake"). Subjective sleepiness was defined as mean deviation from baseline KSS.
Time frame: baseline and 2 months post-treatment
At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.
Time frame: baseline and 2 months post-treatment
Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).
Time frame: baseline and 2 months post-treatment
Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo
Brigham and Women's Hospital
Other
The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02694003
Alcohol-Induced Disorders, Alcohol-Related Disorders
Halifax, Nova Scotia, Canada
View Trial DetailsNCT02243501
Dyssomnias, Mental Disorders
Halifax, Nova Scotia, Canada
View Trial DetailsNCT01960452
Dyssomnias, Mental Disorders
Madison, Wisconsin, United States
View Trial DetailsNCT00816673
Dyssomnias, Mental Disorders
Centre Hospitalier de Rouffach, France
View Trial Details